Alnylam Pharmaceuticals, INC. (ALNY) — 8-K Filings

8-K Filings (15)

• Alnylam Pharmaceuticals Files 8-K — Dec 11, 2025 Risk: low
  On December 10, 2025, Alnylam Pharmaceuticals, Inc. filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits," i
• 8-K Filing — Dec 3, 2025
• Alnylam Pharmaceuticals Enters Material Definitive Agreement — Oct 3, 2025 Risk: medium
  On September 30, 2025, Alnylam Pharmaceuticals, Inc. entered into a material definitive agreement, creating a direct financial obligation. The company, headquar
• Alnylam Pharmaceuticals Reports Material Agreement and Equity Sales — Sep 12, 2025 Risk: medium
  On September 12, 2025, Alnylam Pharmaceuticals, Inc. entered into a material definitive agreement. The company also reported the creation of a direct financial
• Alnylam Pharmaceuticals Files 8-K Report — Sep 10, 2025 Risk: low
  On September 10, 2025, Alnylam Pharmaceuticals, Inc. filed an 8-K report detailing other events and financial statements. The report was filed as of September 1
• Alnylam Pharmaceuticals Appoints New Chief Medical Officer — Jun 18, 2025 Risk: low
  Alnylam Pharmaceuticals, Inc. announced on June 18, 2025, that its Board of Directors appointed Dr. Blake R. Wilson as Chief Medical Officer, effective June 12,
• Alnylam Pharmaceuticals Files 8-K on Governance Matters — May 13, 2025 Risk: low
  Alnylam Pharmaceuticals, Inc. filed an 8-K on May 13, 2025, reporting events that occurred on May 8, 2025. The filing primarily concerns amendments to its artic
• Alnylam Pharmaceuticals Files 8-K Report — Mar 21, 2025 Risk: low
  On March 20, 2025, Alnylam Pharmaceuticals, Inc. filed an 8-K report. The filing indicates "Other Events" as the primary item of disclosure. No specific financi
• Alnylam Pharmaceuticals Appoints New Directors, Adjusts Executive Pay — Mar 5, 2025 Risk: low
  Alnylam Pharmaceuticals, Inc. announced on March 3, 2025, changes in its board of directors and executive compensation. Specifically, the company elected two ne
• Alnylam Pharmaceuticals Reports Financial Condition — Jan 13, 2025 Risk: low
  Alnylam Pharmaceuticals, Inc. filed an 8-K on January 13, 2025, reporting on Results of Operations and Financial Condition as of January 12, 2025. The filing do
• Alnylam Pharmaceuticals Files 8-K on Shareholder Votes — May 20, 2024 Risk: low
  Alnylam Pharmaceuticals, Inc. filed an 8-K on May 20, 2024, reporting on matters submitted to a vote of security holders as of May 16, 2024. The filing details
• Alnylam Pharmaceuticals Appoints New CMO and Director — Mar 4, 2024 Risk: low
  Alnylam Pharmaceuticals, Inc. announced on March 4, 2024, the appointment of Dr. Pushkal Chandra as Chief Medical Officer and the election of Dr. Alnylam Pharma
• Alnylam Files 8-K on Financial Results and Operations — Feb 15, 2024 Risk: medium
  Alnylam Pharmaceuticals, Inc. filed an 8-K on February 15, 2024, to report on its Results of Operations and Financial Condition, and to include Financial Statem
• Alnylam 8-K: Officer Compensation, Director Changes Reported — Jan 19, 2024
  Alnylam Pharmaceuticals, Inc. filed an 8-K on January 19, 2024, reporting events that occurred on January 12, 2024. This filing primarily concerns changes in co
• Alnylam 8-K Signals Upcoming Financial Disclosure — Jan 8, 2024
  Alnylam Pharmaceuticals, Inc. filed an 8-K on January 8, 2024, reporting an event that occurred on January 7, 2024, related to "Results of Operations and Financ

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX